FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.

Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.